• Brain Tumor News Blast Issue 5,656 (Wednesday, April 4, 2018): ONC201 is an experimental, orally bioavailable, first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. It is currently investigated for its safety and efficacy in the following clinical trials: 1) ONC-201 for Recurrent Glioblastomas and H3 K27M-mutant Gliomas; 2) ONC201 in Adults With Recurrent H3 K27M-mutant Glioma and 3) ONC201 in Pediatric H3 K27M Gliomas.

    The full newsletter article can be found here.